Mesenchymal Stem Cell Extracellular Vesicles Reprogram Microglia and Prevent Neurodegeneration in Alzheimer’s Models
Researchers administered the vesicles intranasally over time to female mice genetically engineered to model Alzheimer’s and separately tested them in neurons grown from patients’ induced pluripotent stem cells.
Key Points
- Human amniotic mesenchymal stromal cell extracellular vesicles reduced neuroinflammation in female mice with Alzheimer’s disease.
- Intranasal treatment preserved cognitive performance and synaptic function while altering microglial activity.
- The vesicles also protected patient-derived neurons in a laboratory model of sporadic Alzheimer’s disease.
Researchers just published a study in Translational Neurodegeneration, finding that extracellular vesicles (EVs) from human amniotic mesenchymal stromal cells (hAMSCs) reduced neuroinflammation and neurodegeneration in preclinical Alzheimer’s disease models. The study tested intranasal administration in female 3 × Tg-AD mice and evaluated the vesicles in patient-derived neurons.
Alzheimer’s disease is marked by progressive neuronal and synaptic loss, particularly in the hippocampus and cortex. Its core pathological features include extracellular amyloid-beta accumulation and intracellular neurofibrillary tangles associated with hyperphosphorylated tau.
Inflammation is also considered an active contributor to Alzheimer’s disease progression. Microglia and astrocytes can release inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Persistent activation of these pathways may worsen neuronal damage and other disease-related changes.
Effects on Neuroinflammation and Brain Function
The researchers investigated whether hAMSC-derived EVs could regulate this inflammatory environment. EVs are nanoscale particles that communicate between cells, and those released by mesenchymal stromal cells can carry bioactive molecules associated with anti-inflammatory and neuroprotective activity.
They found that intranasal delivery of the hAMSC-EVs reduced neuroinflammation in female 3 × Tg-AD mice. The treatment also preserved cognitive performance and synaptic function. Behavioral, molecular, histological, and bioinformatic analyses examined changes in cognition, synaptic plasticity, inflammation, and glial function.
The findings indicate that the EV treatment altered microglial activity rather than simply suppressing inflammation broadly. This shift was associated with reduced inflammatory signaling and greater protection of neurons and synapses in the mouse model.
Testing in Patient-Derived Neurons
The researchers also studied glutamatergic neurons generated from induced pluripotent stem cells (iPSCs) obtained from patients with sporadic Alzheimer’s disease. This model allowed the team to evaluate the vesicles in human cells carrying patient-specific disease characteristics.
In these laboratory experiments, hAMSC-EVs protected the patient-derived neurons from disease-associated damage. The results support further investigation of intranasally delivered EVs as a potential cell-free approach for targeting neuroinflammation and neuronal loss.
The work remains preclinical. It was conducted in female Alzheimer’s disease mice and cultured patient-derived neurons, not in people. Additional studies will be needed to assess dosing, durability, safety, manufacturing consistency, and whether the reported effects translate to human Alzheimer’s disease.
Extracellular Vesicle Production and Study Design
The hAMSCs were isolated from term placental amniotic membranes. Researchers characterized the cells using established surface markers and only used preparations meeting predefined criteria for CD13, CD90, CD45, and CD324 expression.
The cells were expanded and cultured in serum-free medium to produce conditioned medium. Researchers collected and filtered this medium before isolating the EVs. Six independent conditioned-medium preparations were generated from six placental donors.
Female 3 × Tg-AD mice were randomly assigned to experimental groups. The animals were maintained under controlled housing conditions, and the study was designed in accordance with ARRIVE guidelines. Together, the animal and patient-derived cell experiments were intended to examine both the biological mechanism and translational relevance of hAMSC-derived EV treatment.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
